CLINICAL TRIALS PROFILE FOR FENOFIBRIC ACID
✉ Email this page to a colleague
All Clinical Trials for Fenofibric Acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00300430 ↗ | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. | Completed | Abbott | Phase 3 | 2006-09-01 | The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood. |
| NCT00300456 ↗ | Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood | Completed | Abbott | Phase 3 | 2006-03-01 | The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood. |
| NCT00300469 ↗ | Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood | Completed | Abbott | Phase 3 | 2006-03-01 | The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood. |
| NCT00300482 ↗ | Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood | Completed | Abbott | Phase 3 | 2006-03-01 | The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood. |
| NCT00808678 ↗ | Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium | Completed | AstraZeneca | Phase 1 | 2008-12-01 | The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies. |
| NCT00826358 ↗ | Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg | Completed | AstraZeneca | Phase 1 | 2008-11-01 | The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies. |
| NCT00839293 ↗ | Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules | Completed | Abbott | Phase 1 | 2009-02-01 | The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Fenofibric Acid
Condition Name
Clinical Trial Locations for Fenofibric Acid
Trials by Country
Clinical Trial Progress for Fenofibric Acid
Clinical Trial Phase
Clinical Trial Sponsors for Fenofibric Acid
Sponsor Name
